by GOT | Dec 11, 2024 | News
AZURITY PHARMACEUTICALS, INC. ANNOUNCES AVAILABILITY OF AZMIRO™ (testosterone cypionate) injection for intramuscular use, CIII FOR IMMEDIATE RELEASE – WOBURN, Mass. (December 11, 2024) – Azurity Pharmaceuticals announced today the availability of Azmiro™,...
by GOT | Nov 14, 2024 | News
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF DANZITEN™ (nilotinib) tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS FOR IMMEDIATE RELEASE – WOBURN, Mass. Nov 14, 2024 – Azurity Pharmaceuticals announced today that the U.S....
by GOT | Sep 3, 2024 | News
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF NYMALIZE® (NIMODIPINE) ORAL SOLUTION 30 MG/5 ML PREFILLED ENFIT® SYRINGE WOBURN, Mass. (September 3, 2024) – Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and...
by GOT | May 6, 2024 | News
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF MYHIBBIN™ (mycophenolate mofetil oral suspension) FOR IMMEDIATE RELEASE WOBURN, Mass. May 6, 2024 – Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and...
by GOT | Jan 24, 2024 | News
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing Media Contact: Liz Flynn, Director, Corporate Communications (781) 281-3225 FOR IMMEDIATE...
by GOT | Sep 27, 2023 | News
Azurity Pharmaceuticals Acquires Slayback Pharma MEDIA ALERT: WOBURN, MA, September 27, 2023 – Azurity Pharmaceuticals, Inc. (“Azurity”) is pleased to announce the closing of its acquisition of Slayback Pharma LLC (“Slayback”) today from existing investors...
Recent Comments